Inactivated Vaccines Global Market Report 2025

Description

Inactivated vaccines, also known as killed vaccines, belong to a category of vaccines that contain viruses or bacteria that have been rendered nonfunctional or inactivated through methods like heat, chemicals, or radiation. These vaccines are specifically developed to elicit an immune response in the vaccinated individual without causing the disease itself.

The primary categories of inactivated vaccines include viral and bacterial vaccines. Viral vaccines are biological preparations containing weakened or inactivated virus components that serve to stimulate the immune system and provide immunity against the targeted viral infection. These viruses are rendered nonfunctional through processes such as solvent detergent treatment, radiation, pH adjustment, heat inactivation, and other methods. These vaccines are typically distributed through hospital pharmacies, retail pharmacies, and other relevant channels.

The inactivated vaccines market research report is one of a series of new reports from The Business Research Company that provides inactivated vaccines market statistics, including inactivated vaccines industry global market size, regional shares, competitors with an inactivated vaccines market share, detailed inactivated vaccines market segments, market trends and opportunities and any further data you may need to thrive in the inactivated vaccines industry. This inactivated vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The inactivated vaccines market size has grown steadily in recent years. It will grow from $6.19 billion in 2024 to $6.44 billion in 2025 at a compound annual growth rate (CAGR) of 4.0%. The growth in the historic period can be attributed to polio eradication efforts, influenza vaccination programs, emerging infectious diseases, regulatory approvals.

The inactivated vaccines market size is expected to see steady growth in the next few years. It will grow to $7.75 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to pandemic preparedness, expanding vaccine coverage, biomanufacturing advancements, health equity initiatives. Major trends in the forecast period include mrna vaccine platforms, combination vaccines, thermostable vaccines, digital vaccine passports.

The rising prevalence of infectious diseases is expected to drive the growth of the inactivated vaccine market in the future. Infectious diseases are illnesses caused by pathogens such as bacteria, viruses, fungi, or parasites, which can spread from one person to another, leading to various symptoms and health complications. Tuberculosis is an example of such diseases. Inactivated vaccines use non-living pathogens to trigger an immune response, effectively preventing illnesses like polio, hepatitis A, and influenza. For example, in November 2023, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, reported an increase in the number of tuberculosis cases in the U.S., rising from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Therefore, the growing prevalence of infectious diseases is fueling the expansion of the inactivated vaccine market.

The increasing immunization initiatives are poised to foster the growth of the inactivated vaccines market in the coming years. Immunization initiatives encompass organized campaigns and efforts designed to vaccinate individuals or communities against specific infectious diseases, ultimately shielding them from these health threats. The expansion of immunization initiatives constitutes a significant factor in the inactivated vaccines market. The proliferation of vaccination campaigns results in higher demand for inactivated vaccines, thereby stimulating market growth and encouraging investments in research and development. For instance, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicates that vaccines annually prevent 4-5 million lives from being lost globally due to infectious diseases like hepatitis, diphtheria, tetanus, pertussis (whooping cough), measles, and polio. Furthermore, in 2022, approximately 84% of infants worldwide received three doses of the polio vaccine. Similarly, an estimated 84% of infants in countries utilizing oral polio vaccine (OPV) received their initial inactivated polio vaccine (IPV) dose during the same year. Consequently, the growing immunization initiatives are a driving force behind the expansion of the inactivated vaccines market.

Prominent companies engaged in the inactivated vaccines market are introducing cutting-edge and advanced inactivated vaccines to maintain their market positioning. Inactivated vaccines encompass vaccines containing non-live virus particles, bacteria, or other pathogens that have been cultured and subsequently rendered non-viable to eliminate their disease-causing capabilities. As an illustration, in January 2022, GSK PLC, a UK-based pharmaceutical and biotechnology enterprise, unveiled a novel inactivated vaccine known as Shingrix, designed for shingles protection. Shingrix is a non-live, recombinant subunit adjuvanted vaccine administered via intramuscular injection in two doses. Initially indicated for individuals aged 50 and older, its application has recently been expanded to encompass individuals aged 18 and older who face an elevated risk of developing shingles due to immunodeficiency or immunosuppression triggered by a known medical condition or medical treatment.

In April 2022, Albumedix Ltd., a UK-based biotechnology company, forged a collaboration with Valneva SE. This collaborative venture between Albumedix Ltd. and Valneva is expected to contribute to an augmentation in the production capacity of inactivated COVID-19 vaccines. The increased production capacity is intended to cater to the escalating demand for COVID-19 vaccines. Valneva SE is a French biotechnology enterprise with expertise in the discovery, manufacture, and distribution of inactivated vaccines designed to combat infectious diseases.

Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.,.

North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inactivated vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The inactivated vaccines market consists of sales of whole-cell inactivated vaccines, subunit or protein subunit vaccines, conjugate vaccines and toxoid vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inactivated Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inactivated vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inactivated vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inactivated vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Viral Vaccine; Bacterial Vaccine
2) By Method Of Inactivation: Solvent Detergent; Radiation; pH Concentration; Heat Inactivation; Other Methods Of Inactivation
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
Subsegments:
1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV); Inactivated Influenza Vaccine; Inactivated Hepatitis A Vaccine; Inactivated Rabies Vaccine
2) By Bacterial Vaccine: Inactivated Typhoid Vaccine; Inactivated Cholera Vaccine; Inactivated Pertussis Vaccine; Inactivated Plague Vaccine
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Sinopharm Group Co. Ltd.; Merck & Co. Inc.; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r28303

1. Executive Summary

2. Inactivated Vaccines Market Characteristics

3. Inactivated Vaccines Market Trends And Strategies

4. Inactivated Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Inactivated Vaccines Growth Analysis And Strategic Analysis Framework

5.1. Global Inactivated Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Inactivated Vaccines Market Growth Rate Analysis
5.4. Global Inactivated Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Inactivated Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Inactivated Vaccines Total Addressable Market (TAM)

6. Inactivated Vaccines Market Segmentation

6.1. Global Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Viral Vaccine
Bacterial Vaccine
6.2. Global Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Solvent Detergent
Radiation
pH Concentration
Heat Inactivation
Other Methods Of Inactivation
6.3. Global Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Other Distribution Channels
6.4. Global Inactivated Vaccines Market, Sub-Segmentation Of Viral Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Inactivated Poliovirus Vaccine (IPV)
Inactivated Influenza Vaccine
Inactivated Hepatitis A Vaccine
Inactivated Rabies Vaccine
6.5. Global Inactivated Vaccines Market, Sub-Segmentation Of Bacterial Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Inactivated Typhoid Vaccine
Inactivated Cholera Vaccine
Inactivated Pertussis Vaccine
Inactivated Plague Vaccine

7. Inactivated Vaccines Market Regional And Country Analysis

7.1. Global Inactivated Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Inactivated Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inactivated Vaccines Market

8.1. Asia-Pacific Inactivated Vaccines Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inactivated Vaccines Market

9.1. China Inactivated Vaccines Market Overview
9.2. China Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inactivated Vaccines Market

10.1. India Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inactivated Vaccines Market

11.1. Japan Inactivated Vaccines Market Overview
11.2. Japan Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inactivated Vaccines Market

12.1. Australia Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inactivated Vaccines Market

13.1. Indonesia Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inactivated Vaccines Market

14.1. South Korea Inactivated Vaccines Market Overview
14.2. South Korea Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inactivated Vaccines Market

15.1. Western Europe Inactivated Vaccines Market Overview
15.2. Western Europe Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inactivated Vaccines Market

16.1. UK Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inactivated Vaccines Market

17.1. Germany Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inactivated Vaccines Market

18.1. France Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inactivated Vaccines Market

19.1. Italy Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inactivated Vaccines Market

20.1. Spain Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inactivated Vaccines Market

21.1. Eastern Europe Inactivated Vaccines Market Overview
21.2. Eastern Europe Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inactivated Vaccines Market

22.1. Russia Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inactivated Vaccines Market

23.1. North America Inactivated Vaccines Market Overview
23.2. North America Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inactivated Vaccines Market

24.1. USA Inactivated Vaccines Market Overview
24.2. USA Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inactivated Vaccines Market

25.1. Canada Inactivated Vaccines Market Overview
25.2. Canada Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inactivated Vaccines Market

26.1. South America Inactivated Vaccines Market Overview
26.2. South America Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inactivated Vaccines Market

27.1. Brazil Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inactivated Vaccines Market

28.1. Middle East Inactivated Vaccines Market Overview
28.2. Middle East Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inactivated Vaccines Market

29.1. Africa Inactivated Vaccines Market Overview
29.2. Africa Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inactivated Vaccines Market Competitive Landscape And Company Profiles

30.1. Inactivated Vaccines Market Competitive Landscape
30.2. Inactivated Vaccines Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sinopharm Group Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Inactivated Vaccines Market Other Major And Innovative Companies

31.1. GlaxoSmithKline plc
31.2. Takeda Pharmaceutical Company Limited
31.3. Astellas Pharma Inc.
31.4. CSL Limited
31.5. Daiichi Sankyo Company Limited
31.6. Mitsubishi Tanabe Pharma Corporation
31.7. Novavax Inc.
31.8. Zydus Lifesciences Ltd.
31.9. Sinovac Biotech Ltd.
31.10. Biological E Limited
31.11. Hualan Biological Engineering Inc.
31.12. CanSino Biologics Inc.
31.13. Shenzhen Kangtai Biological Products Co. Ltd.
31.14. Serum Institute of India Pvt. Ltd.
31.15. Beijing Tiatan Biological Products Co. Ltd.

32. Global Inactivated Vaccines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inactivated Vaccines Market

34. Recent Developments In The Inactivated Vaccines Market

35. Inactivated Vaccines Market High Potential Countries, Segments and Strategies

35.1 Inactivated Vaccines Market In 2029 - Countries Offering Most New Opportunities
35.2 Inactivated Vaccines Market In 2029 - Segments Offering Most New Opportunities
35.3 Inactivated Vaccines Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer